Tags

Type your tag names separated by a space and hit enter

MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
Diagn Microbiol Infect Dis. 2009 Feb; 63(2):217-22.DM

Abstract

The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a longitudinal antimicrobial surveillance study that has been in existence since 1997 in centers that are actively prescribing meropenem. This report examines the results from the study in Europe in 2007. A total of 5208 isolates were examined for activity (MIC) of meropenem and other broad-spectrum antibacterial comparators. Cumulative susceptibility rates using Clinical and Laboratory Standards Institute criteria against all methicillin-susceptible staphylococci were imipenem (97.7%) > meropenem (97.3%) > piperacillin/tazobactam (96.2%) > tobramycin (94.2%) > gentamicin (92.0%) > ciprofloxacin (84.0%) > ceftazidime (39.8%). Against all species of Enterobacteriaceae, the rates were meropenem (99.4%) > imipenem (98.3%) > tobramycin (92.0%) > gentamicin (89.5%) > ceftazidime (86.2%) > piperacillin/tazobactam (85.5%) > ciprofloxacin (84.2%). Meropenem was most effective against the nonfermenters, although multidrug-resistant Acinetobacter spp. and imipenem-resistant Pseudomonas aeruginosa strains were reported. The continued need for surveillance studies such as MYSTIC is exemplified, and results from these types of surveillance can, hopefully, help in the correct choice of empiric therapy.

Authors+Show Affiliations

Infection Discovery Department, AstraZeneca, SK10 4TF Macclesfield, UK. osirispjt@tiscali.co.uk

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19070453

Citation

Turner, Philip J.. "MYSTIC Europe 2007: Activity of Meropenem and Other Broad-spectrum Agents Against Nosocomial Isolates." Diagnostic Microbiology and Infectious Disease, vol. 63, no. 2, 2009, pp. 217-22.
Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis. 2009;63(2):217-22.
Turner, P. J. (2009). MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagnostic Microbiology and Infectious Disease, 63(2), 217-22. https://doi.org/10.1016/j.diagmicrobio.2008.11.004
Turner PJ. MYSTIC Europe 2007: Activity of Meropenem and Other Broad-spectrum Agents Against Nosocomial Isolates. Diagn Microbiol Infect Dis. 2009;63(2):217-22. PubMed PMID: 19070453.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. A1 - Turner,Philip J, Y1 - 2008/12/12/ PY - 2008/06/26/received PY - 2008/08/25/revised PY - 2008/11/05/accepted PY - 2008/12/17/entrez PY - 2008/12/17/pubmed PY - 2009/8/8/medline SP - 217 EP - 22 JF - Diagnostic microbiology and infectious disease JO - Diagn. Microbiol. Infect. Dis. VL - 63 IS - 2 N2 - The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a longitudinal antimicrobial surveillance study that has been in existence since 1997 in centers that are actively prescribing meropenem. This report examines the results from the study in Europe in 2007. A total of 5208 isolates were examined for activity (MIC) of meropenem and other broad-spectrum antibacterial comparators. Cumulative susceptibility rates using Clinical and Laboratory Standards Institute criteria against all methicillin-susceptible staphylococci were imipenem (97.7%) > meropenem (97.3%) > piperacillin/tazobactam (96.2%) > tobramycin (94.2%) > gentamicin (92.0%) > ciprofloxacin (84.0%) > ceftazidime (39.8%). Against all species of Enterobacteriaceae, the rates were meropenem (99.4%) > imipenem (98.3%) > tobramycin (92.0%) > gentamicin (89.5%) > ceftazidime (86.2%) > piperacillin/tazobactam (85.5%) > ciprofloxacin (84.2%). Meropenem was most effective against the nonfermenters, although multidrug-resistant Acinetobacter spp. and imipenem-resistant Pseudomonas aeruginosa strains were reported. The continued need for surveillance studies such as MYSTIC is exemplified, and results from these types of surveillance can, hopefully, help in the correct choice of empiric therapy. SN - 1879-0070 UR - https://www.unboundmedicine.com/medline/citation/19070453/MYSTIC_Europe_2007:_activity_of_meropenem_and_other_broad_spectrum_agents_against_nosocomial_isolates_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(08)00474-4 DB - PRIME DP - Unbound Medicine ER -